SAN FRANCISCO, March 1, 2011 /PRNewswire/ — Nektar
NKTR) President and Chief Executive Officer, Howard W. Robin,
is scheduled to present at the 31st Annual Cowen and Company
Healthcare Conference at the Boston Marriott Copley Place on
Tuesday, March 8, 2011 at 11:00 a.m. Eastern time.
The presentation will be accessible via a Webcast through a link
posted on the Investor Relations, Events Calendar section of the
Nektar website http://www.nektar.com. This
webcast will be available for replay until April 8, 2011.
Nektar Therapeutics is a biopharmaceutical company developing
novel therapeutics based on its PEGylation and advanced polymer
conjugation technology platforms. Nektar has a robust R&D
pipeline of potentially high-value therapeutics in oncology, pain
and other areas. In the area of pain, Nektar has an exclusive
worldwide license agreement with AstraZeneca for Nektar’s oral
NKTR-118 late-stage development program to treat opioid-induced
constipation and its NKTR-119 earlier stage development program for
the treatment of pain without constipation side effects.
NKTR-181 is a novel mu-opioid analgesic molecule that is
being prepared for Phase 1 clinical studies. In oncology, NKTR-102,
a novel topoisomerase I-inhibitor, is being evaluated in Phase 2
clinical studies for the treatment of ovarian, breast and
colorectal cancers. NKTR-105, a novel anti-mitotic agent, is in a
Phase 1 clinical study in cancer patients with refractory solid
Nektar’s technology has enabled seven approved products in the
U.S. or Europe through partnerships with leading biopharmaceutical
companies, including UCB’s Cimzia(R) for Crohn’s disease and
rheumatoid arthritis, Roche’s PEGASYS(R) for hepatitis C and
Amgen’s Neulasta(R) for neutropenia.
Nektar is headquartered in S